Foamix

Given Foamix Pharmaceuticals’ higher possible upside, equities analysts plainly believe Foamix Pharmaceuticals is more favorable than Tauriga Sciences.

ARK Investment Management LLC increased its holdings in shares of Foamix Pharmaceuticals by 25.0% during the 2nd quarter.

As a group, sell-side analysts forecast that Foamix Pharmaceuticals will post -1.64 earnings per share for the current fiscal year.

Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price objective on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 7th.

Finally, Trexquant Investment LP increased its position in Foamix Pharmaceuticals by 205.6% in the third quarter.

Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the company, reports.

Cantor Fitzgerald began coverage on shares of Foamix Pharmaceuticals in a report on Thursday, October 11th.